DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Martin M, Holmes FA, Ejlertsen B. et al.
Neratinib after trastuzumab (T)-based adjuvant therapy in early-stage HER2+ breast cancer (BC): 5-year analysis of the phase III ExteNET trial.
Ann Oncol 2017;
28 (Suppl. 05) v43-v67 Abstr. 149O
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.